[1]张汗磊,王 松,陈 思,等.粪便肿瘤M2型丙酮酸激酶在结直肠癌和腺瘤性息肉中的诊断价值[J].医学信息,2021,34(12):78-81.[doi:10.3969/j.issn.1006-1959.2021.12.021]
　ZHANG Han-lei,WANG Song,CHEN Si,et al.The Diagnostic Value of Stool Tumor M2 Pyruvate Kinase in Colorectal Cancer and Adenomatous Polyps[J].Medical Information,2021,34(12):78-81.[doi:10.3969/j.issn.1006-1959.2021.12.021]
点击复制

粪便肿瘤M2型丙酮酸激酶在结直肠癌和腺瘤性息肉中的诊断价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年12期
页码:
78-81
栏目:
论著
出版日期:
2021-06-15

文章信息/Info

Title:
The Diagnostic Value of Stool Tumor M2 Pyruvate Kinase in Colorectal Cancer and Adenomatous Polyps
文章编号:
1006-1959（2021）12-0078-04
作者:
张汗磊; 王 松; 陈 思; 等
（安徽医科大学附属省立医院消化内科，安徽 合肥 230001）
Author(s):
ZHANG Han-lei; WANG Song; CHEN Si; et al
(Department of Gastroenterology,Provincial Hospital Affiliated to Anhui Medical University,Hefei 230001,Anhui,China)
关键词:
结直肠癌; 腺瘤性息肉; 粪便肿瘤M2型丙酮酸激酶
Keywords:
Colorectal cancer; Adenomatous polyps; Stool tumor M2 pyruvate kinase
分类号:
R735.3
DOI:
10.3969/j.issn.1006-1959.2021.12.021
文献标志码:
A
摘要:
目的 探讨粪便肿瘤M2型丙酮酸激酶（Tu M2-PK）浓度在结直肠癌和腺瘤性息肉中的诊断价值。方法 收集2019年10月~2020年8月在安徽省立医院经术后病理明确诊断的结直肠癌患者50例，腺瘤性息肉患者47例，以及正常人群31例粪便标本，采用粪便Tu M2-PK酶联免疫快速试剂检测粪便标本中Tu M2-PK浓度,并分析Tu M2-PK浓度与结直肠癌的分期、位置和腺瘤性息肉的数目、大小的关系，评估TU M2-PK在结直肠癌和腺瘤性息肉发展和诊断中的作用。结果 粪便TuM2-PK在结直肠癌患者中的浓度高于腺瘤性息肉组和正常对照组，差异有统计学意义（P＜0.05）；以浓度大于4U/ml为诊断结直肠癌的cut-off值，在诊断结直肠癌的阳性率为82%；Tu M2-PK水平与结直肠癌的分期可能有关（P＜0.05），与结直肠癌的位置无关，ROC曲线确定Tu M2-PK诊断腺瘤性息肉的最佳截断值为2.62 U/ml，敏感度为51.06%，特异度为80.65%，约登指数为0.317。浓度与腺瘤性息肉的数目和大小无关，ROC曲线下面积为0.704（95%CI 0.588~0.819）。结论 粪便TU M2-PK在腺瘤性息肉中无特异性诊断价值，在结直肠癌中浓度升高明显，是一种良好的肿瘤标志物，其可能参与结直肠癌的发生、发展过程。
Abstract:
Objective To investigate the diagnostic value of fecal tumor M2 pyruvate kinase (Tu M2-PK) concentration in colorectal cancer and adenomatous polyps.Methods From October 2019 to August 2020, 50 cases of colorectal cancer patients, 47 cases of adenomatous polyps, and 31 fecal specimens of normal people who were diagnosed by pathology in Anhui Provincial Hospital from October 2019 to August 2020 were collected.The fecal Tu M2-PK enzyme-linked immunoassay rapid reagent was used to detect the concentration of Tu M2-PK in stool samples, and the relationship between the concentration of Tu M2-PK and the stage and location of colorectal cancer and the number and size of adenomatous polyps was analyzed.To evaluate the role of TU M2-PK in the development and diagnosis of colorectal cancer and adenomatous polyps.Results The concentration of TuM2-PK in stool in patients with colorectal cancer was higher than that in the adenomatous polyp group and the normal control group,the difference was statistically significant (P＜0.05);Taking a concentration greater than 4 U/ml as the cut-off value for the diagnosis of colorectal cancer, the positive rate in the diagnosis of colorectal cancer was 82%; Tu M2-PK level may be related to the staging of colorectal cancer (P＜0.05),regardless of the location of colorectal cancer, the ROC curve determined that the best cut-off value of Tu M2-PK for the diagnosis of adenomatous polyps was 2.62 U/ml, the sensitivity was 51.06%, the specificity was 80.65%, and the Youden index was 0.317.The concentration had nothing to do with the number and size of adenomatous polyps, and the area under the ROC curve was 0.704 (95% CI 0.588~0.819).Conclusion Stool TU M2-PK has no specific diagnostic value in adenomatous polyps. It has a significant increase in concentration in colorectal cancer. It is a good tumor marker and may be involved in the occurrence and development of colorectal cancer.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424. [2]Fitzmaurice C,Allen C,Barber RM,et al.Global, Regional, and National Cancer Incidence,Mortality,Years of Life Lost,Years Lived With Disability,and Disability-Adjusted Life-years for 32 Cancer Groups,1990 to 2015:A Systematic Analysis for the Global Burden of Disease Study[J].JAMA Oncol,2017,3(4):524-548. [3]Allemani C,Matsuda T,Di CV,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075. [4]Hardt PD,Toepler M,Ngoumou BK,et al.Measurement of fecal pyruvate kinase type M2(tumor M2-PK)concentrations in patients with gastric cancer,colorectal cancer,colorectal adenomas and controls[J].Anticancer Research,2003,23(2A):851. [5]Rigi F,Jannatabad A,Izanloo A,et al.Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps[J].BMC Gastroenterology,2020,20(1):241. [6]Lee JK,Liles EG,Bent S,et al.Accuracy of fecal immunochemical tests for colorectal cancer:systematic review and meta-analysis[J].Annals of Internal Medicine,2014,160(3):171. [7]Katsoula A,Paschos P,Haidich AB,et al.Diagnostic Accuracy of Fecal Immunochemical Test in Patients at Increased Risk for Colorectal Cancer:A Meta-analysis[J].Jama Internal Medicine,2017,177(8):1110-1118. [8]Zaccaro C,Saracino IM,Fiorini G,et al.Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT[J].Internal&Emergency Medicine,2017,12(3):1-7. [9]Leen R,Seng-Lee C,Holleran G,et al.Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort[J].Eur J Gastroenterol Hepatol,2014,26(5):514-518. [10]Yong CK,Kim JH,Cheung DY,et al.The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test[J].Gut and Liver,2015,9(5):641-648. [11]Tonus C,Sellinger M,Koss K,et al.Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening:A meta-analysis[J].World Journal of Gastroenterology,2012,18(30):4004-4011. [12]Bond AD,Burkitt MD,Sawbridge D,et al.Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort[J].J Gastrointestin Liver Dis,2016,25(1):71-77. [13]Keenan J, Aitchison A, Leaman J,et al.Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms[J].The New Zealand Medical Journal,2019,132(1501):48-56.

相似文献/References:

[1]张西园.糖尿病与结直肠癌患者预后相关研究进展[J].医学信息,2018,31(01):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
　ZHANG Xi-yuan.Research Progress in the Relationship between Diabetes and the Prognosis of Colorectal Cancer[J].Medical Information,2018,31(12):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
[2]陈学敏,彭 琼.中性粒细胞与淋巴细胞比值联合癌胚抗原对结直肠癌早期诊断的研究[J].医学信息,2019,32(02):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
　CHEN Xue-min,PENG Qiong.Early Diagnosis of Colorectal Cancer by Neutrophil-lymphocyte Ratio Combined with Carcinoembryonic Antigen[J].Medical Information,2019,32(12):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
[3]李在明,魏正强.外泌体在结直肠癌中的研究进展[J].医学信息,2019,32(03):42.[doi:10.3969/j.issn.1006-1959.2019.03.014]
　LI Zai-ming,WEI Zheng-qiang.Research Progress of Exosomes in Colorectal Cancer[J].Medical Information,2019,32(12):42.[doi:10.3969/j.issn.1006-1959.2019.03.014]
[4]周玲玲,鞠乐乐,颜 玉.结直肠癌患者手术前后血清IGF-1水平变化及临床价值分析[J].医学信息,2019,32(04):121.[doi:10.3969/j.issn.1006-1959.2019.04.039]
　ZHOU Ling-ling,JU Le-le,YAN Yu.Analysis of Changes and Clinical Value of Serum IGF-1 Levels in Patients with Colorectal Cancer before and after Operation[J].Medical Information,2019,32(12):121.[doi:10.3969/j.issn.1006-1959.2019.04.039]
[5]陈小玉,白 鍊,贺春香.结直肠癌根治手术患者营养状况调查[J].医学信息,2019,32(05):83.[doi:10.3969/j.issn.1006-1959.2019.05.025]
　CHEN Xiao-yu,BAI Lian,HE Chun-xiang.Investigation on Nutritional Status of Patients Undergoing Radical Surgery for Colorectal Cancer[J].Medical Information,2019,32(12):83.[doi:10.3969/j.issn.1006-1959.2019.05.025]
[6]李大略,赵资文,刘兆礼,等.加速康复外科对合并有糖尿病的结直肠癌患者术后炎症反应与营养代谢的影响[J].医学信息,2019,32(07):67.[doi:10.3969/j.issn.1006-1959.2019.07.021]
　LI Da-lue,ZHAO Zi-wen,LIU Zhao-li,et al.Effect of Accelerated Rehabilitation Surgery on Postoperative Inflammatory Response and Nutrient Metabolism in Patients with Colorectal Cancer Complicated with Diabetes[J].Medical Information,2019,32(12):67.[doi:10.3969/j.issn.1006-1959.2019.07.021]
[7]王逸飞,王 志,左宏波,等.伊利替康联合替吉奥在晚期结直肠癌治疗的临床研究[J].医学信息,2019,32(07):158.[doi:10.3969/j.issn.1006-1959.2019.07.049]
　WANG Yi-fei,WANG Zhi,ZUO Hong-bo,et al.Clinical Study of Irinotecan Combined with Tegafur,Gimeracil and Oteracil Porassium Capsulesin the Treatment of Advanced Colorectal Cancer[J].Medical Information,2019,32(12):158.[doi:10.3969/j.issn.1006-1959.2019.07.049]
[8]谢 勇,涂经楷,肖明盛,等.腹腔镜与传统开腹结直肠癌根治术手术效果对比[J].医学信息,2019,32(11):98.[doi:10.3969/j.issn.1006-1959.2019.11.026]
　XIE Yong,TU Jing-kai,XIAO Ming-sheng,et al.Comparative of Laparoscopic and Traditional Open Radical Rectal Cancer Radical Operation[J].Medical Information,2019,32(12):98.[doi:10.3969/j.issn.1006-1959.2019.11.026]
[9]李莎莎,李 芳,王卫峰,等.地中海饮食与结直肠癌的相关研究[J].医学信息,2019,32(15):6.[doi:10.3969/j.issn.1006-1959.2019.15.003]
　LI Sha-sha,LI Fang,WANG Wei-feng,et al.Correlation between Mediterranean Diet and Colorectal Cancer[J].Medical Information,2019,32(12):6.[doi:10.3969/j.issn.1006-1959.2019.15.003]
[10]孙 峰,鲍扬漪,朱 婷,等.晚期结直肠癌抗血管生成靶向治疗研究进展[J].医学信息,2019,32(17):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]
　SUN Feng,BAO Yang-yi,ZHU Ting,et al.Advances in Anti-angiogenesis Targeted Therapy for Advanced Colorectal Cancer[J].Medical Information,2019,32(12):1.[doi:10.3969/j.issn.1006-1959.2019.17.001]

更新日期/Last Update: 1900-01-01